Medicare Part D can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. The plan may require prior authorization or a formulary exception. CMS directs these requests through Part D [8]. The trials behind the label required 15 or more breathing events an hour on a sleep study [5].
Basic Part D generally excludes drugs used solely for weight loss [3]. Our guide to Medicare GLP-1 coverage explains the separate Bridge program for eligible weight-management prescriptions. CMS says Zepbound prescribed for sleep apnea goes through the Part D plan instead [8].
Why sleep apnea is a different claim
A claim is judged by its use, not its molecule. Zepbound has two uses on its label. One is weight reduction, and the other is moderate to severe obstructive sleep apnea in adults with obesity [5]. The second is not a weight-loss use.
A 2026 study used 2023 and 2024 claims for adults continuously enrolled in Medicare fee-for-service Parts A, B, and D [2]. It listed four covered GLP-1 uses [2]. Two are type 2 diabetes and heart disease with overweight or obesity. The others are sleep apnea with obesity and a fatty liver disease [2]. About 1.2 million beneficiaries had obesity without one of the covered diagnoses under the study’s definition [2].
The comparison of Zepbound and Mounjaro explains why the branded prescription matters even though both contain tirzepatide. For Part D, confirm the indication on the prescription and the plan’s requirements.
The diagnosis has to be on paper
The label’s trials defined moderate to severe apnea by a number. They required an apnea-hypopnea index of 15 or more events an hour [5]. That was measured by polysomnogram, an overnight sleep study [5]. The trials also required a BMI of 30 or more [5]. People with type 2 diabetes were excluded [5].
The index itself depends on a scoring rule. A hypopnea can be counted at a 4% drop in oxygen, or at a 3% drop or an arousal [4]. One study rescored a sample of 2,057 people both ways [4]. Under the stricter 4% rule, 60% moved to a milder grade or lost the diagnosis [4].
That shift changed who appeared eligible for tirzepatide under the study’s criteria. Of those eligible under the 3% oxygen drop or arousal rule, 180 people (35%) no longer qualified under the 4% rule [4]. Women were reclassified more often than men [4]. The sleep report is therefore the document to read first.
What the trials measured
SURMOUNT-OSA consisted of two 52-week trials [1]. One enrolled people not using positive airway pressure (PAP), and the other enrolled people already using it. Starting indexes averaged 51.5 and 49.5 events an hour [1].
The sleep apnea trial guide explains how the trials handled breathing-device use. At 52 weeks, the trial without PAP found declines of 25.3 events per hour with tirzepatide and 5.3 with placebo [1]. Among people already using PAP at enrollment, the index fell 29.3 and 5.5 events per hour, respectively [1]. That trial asked participants to pause PAP for seven days before the endpoint sleep study [5].
Eligible is not the same as filled
Among 16,474,786 Medicare fee-for-service beneficiaries with Part D, 35.1% had a covered GLP-1 condition [2]. Of those, 16.5% had a claim [2]. The authors say eligibility alone may not become treatment without addressing affordability [2].
The study measured claims across multiple covered GLP-1 uses in fee-for-service Medicare [2]. It did not report that 16.5% of people with sleep apnea filled Zepbound. Use the insurance worksheet to record what your plan says about coverage for your prescription. Ask about any authorization or exception before assuming it will be covered.
What it costs without coverage
The label lists 10 mg and 15 mg weekly as maintenance doses for sleep apnea [5]. The following prices are from LillyDirect as checked November 14, 2026.
LillyDirect publishes a self-pay price for each strength. At 10 mg and 15 mg it reads “Starting at $449/month” “when you refill within 45 days” [7]. Miss that window and the footnote applies: “$699 for 10mg” and “$699 for 15mg” [7]. A month is 28 days and one KwikPen [7].
The Zepbound savings guide for Medicare explains how to tell the commercial savings card from the separate self-pay program. Lilly’s commercial card excludes Medicare enrollees [6]. Check the self-pay terms for the exact product before filling.